COMPANY PROFILE

Morphogenesis

Explore full profile

Developing novel cell and gene therapies

Tampa, United StatesFounded 1995Biotech & Life Sciences

Valuation $50–100M Last recorded · 2022

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Morphogenesis

Morphogenesis, Inc. is a clinical-stage biotechnology company focused on developing novel cell and gene therapies to treat chronic diseases, particularly cancer. The company operates in the biopharmaceutical market, targeting both healthcare providers and patients seeking advanced treatment options. Morphogenesis' core business model revolves around the research, development, and clinical trials of its proprietary immunotherapies, which aim to engage the body's innate intelligence to fight diseases. Revenue is primarily generated through partnerships, grants, and future commercialization of its therapies. Currently, the company is conducting a first-in-human clinical study for cutaneous cancers and expanding the use of its intralesional cancer vaccine for advanced Merkel cell carcinoma and cutaneous squamous cell carcinoma.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 1995
Headquarters: Tampa, United States
Employees: 32
Open positions: None listed
Dealroom signal: 56.1/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, DNA, Genetics and genomics, Spinout, Genome Engineering, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Investment activity: 1 company, latest May 2023
Capital deployed: —
Preferred round: MERGER
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
MERGER✓Other financing	May 2023	$0	—	Cohbar	↗
EARLY VC✓Equity / VC	Jul 2022	$9.1M	$36M	Undisclosed	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Morphogenesis website traffic

Latest recorded traffic for Morphogenesis is 200 monthly website visits, down 70.1% over the last three months. Morphogenesis's team grew 39.1% over the past year.

Latest monthly visits200 3-month web change-70.1% 1-year team growth+39.1%

Monthly website visitsOct 2017–Jan 2024

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ANAntegenesGenetic tests for personalized cancer risk prevention	Tartu, Estonia	Operational	11	$3.4M	$7M
LULucencePrecision oncology company dedicated to creating state-of-the-art, highly sensitive liquid biopsy tests for early disease detection and personalized treatment selection	Palo Alto, United States	Operational
NTNucleome TherapeuticsDecoding the dark matter of the human genome to discover first-in-class precision medicine	Oxford, United Kingdom	Operational
FEFemtogenixDNA-interactive payloads for antibody-drug conjugates	St Albans, United Kingdom	Operational
HBHexagon BioA data-driven biotech company developing targeted small molecule therapeutics	Menlo Park, United States	Operational
OBOctant BioDeveloping synthetic technology and applying next-generation DNA sequencing, gene synthesis, and gene editing to discover safer, more effective, cheaper drugs	Emeryville, United States	Operational
ETEngender TechnologiesDeveloped a technology to separate X- and Y-bearing bull sperm cells	Auckland, New Zealand	Acquired
KBKangleweishi BiotechnologyA high-tech enterprise focusing on the development and production of innovative biomedicine in the public health field	China	Operational